GBA1 and Parkinson disease: Therapeutic interventions such as Ambroxol, enzyme replacement therapy (ERT), and substrate reduction therapy (SRT) offer promising avenues to modulate biomarkers in peripheral tissues, including fibroblasts, in GBA1-associated PD.